Glucotrack seeks FDA approval for clinical study of CBGM technology

Glucotrack has submitted an IDE application to the US FDA, seeking approval to begin a clinical study in the US for its CBGM technology. Glucotrack will proceed with the planned US trial after the FDA reviews and approves the IDE application. The device delivers real-time data and may address needs for people with diabetes. Credit: Chay_Tee / Shutterstock.com. Glucotrack has submitted an investigational device exemption (IDE) application to the US Food and Drug Administration (FDA), seeking approval to begin a clinical study in the US for its continuous blood glucose monitoring (CBGM) technology. The IDE submission marks a significant milestone…

Source: Medical Device Network